ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      Subscribe Login/Register Profile Icon
      S&P 500
      5,460.48
      -0.41%
      US Tech 100
      19,181.60
      -0.43%
      Dow Jones
      39,118.86
      -0.12%
      Brent Oil
      85.245
      0.16%
      Bitcoin
      63,299.84
      1.00%
      Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ
      6. Incyte Corporation (INCY)

      7. Incyte Corporation (INCY) News

      INCY

      Incyte (INCY)

      Incyte Corporation
      		Date:
      Sort by:
       Showing the most relevant articles for your search:NASDAQ:INCY
      DateTimeSourceHeadlineSymbolCompany
      05/04/20224:15PMBusiness WireIncyte to Present at Upcoming Investor ConferenceNASDAQ:INCYIncyte Corporation
      05/04/20228:41AMTipRanksSVB Securities Keeps a Sell Rating on Incyte (INCY)NASDAQ:INCYIncyte Corporation
      05/03/20228:05AMTipRanksAnalysts’ Top Healthcare Picks: Alnylam Pharma (ALNY), Incyte (INCY)NASDAQ:INCYIncyte Corporation
      05/03/20227:16AMEdgar (US Regulatory)Current Report Filing (8-k)NASDAQ:INCYIncyte Corporation
      05/03/20227:00AMBusiness WireIncyte Reports 2022 First Quarter Financial Results and Provides Updates on Key Clinical ProgramsNASDAQ:INCYIncyte Corporation
      04/29/20228:03AMEdgar (US Regulatory)Additional Proxy Soliciting Materials (definitive) (defa14a)NASDAQ:INCYIncyte Corporation
      04/28/20224:05PMBusiness WireIncyte and Maruho Announce Strategic Alliance Agreement for Ruxolitinib Cream in JapanNASDAQ:INCYIncyte Corporation
      04/28/20228:39AMTipRanksJMP Securities Keeps Their Buy Rating on Incyte (INCY)NASDAQ:INCYIncyte Corporation
      04/22/20229:40AMBusiness WireIncyte Announces Positive CHMP Opinion for Capmatinib (Tabrecta®) for the Treatment of METex14 Advanced Non-Small Cell Lung CancerNASDAQ:INCYIncyte Corporation
      04/21/20228:22AMEdgar (US Regulatory)Current Report Filing (8-k)NASDAQ:INCYIncyte Corporation
      04/12/20224:13PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:INCYIncyte Corporation
      04/12/20228:00AMBusiness WireIncyte to Report First Quarter Financial ResultsNASDAQ:INCYIncyte Corporation
      04/11/202212:05PMTipRanksIncyte (INCY) Gets a Buy Rating from JMP SecuritiesNASDAQ:INCYIncyte Corporation
      04/07/20229:48PMTipRanksRBC Capital Sticks to Its Buy Rating for Incyte (INCY)NASDAQ:INCYIncyte Corporation
      04/04/20224:01PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:INCYIncyte Corporation
      04/04/20224:01PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:INCYIncyte Corporation
      04/04/20224:01PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:INCYIncyte Corporation
      03/27/20227:15PMTipRanksMizuho Securities Maintains a Hold Rating on Incyte (INCY)NASDAQ:INCYIncyte Corporation
      03/27/20227:15PMBusiness WireIncyte meldet 52-Wochen-Daten aus dem Phase-3-Programm TRuE-V zur Evaluierung von Ruxolitinib-Creme (Opzelura™) bei Patienten mit VitiligoNASDAQ:INCYIncyte Corporation
      03/26/20229:00PMBusiness WireIncyte publie des données à 52 semaines du programme TRuE-V de Phase 3 évaluant la crème au ruxolitinib (Opzelura™) chez des patients atteints de vitiligoNASDAQ:INCYIncyte Corporation
      03/26/202211:20AMPR Newswire (US)Nearly 40% of Adults with Alopecia Areata Taking OLUMIANT® 4-mg Saw at Least 80% Scalp Hair Coverage at 52 Weeks in Lilly's Pivotal Phase 3 StudiesNASDAQ:INCYIncyte Corporation
      03/26/202210:40AMBusiness WireIncyte Announces 52-Week Data From the Phase 3 TRuE-V Program Evaluating Ruxolitinib Cream (Opzelura™) in Patients With VitiligoNASDAQ:INCYIncyte Corporation
      03/25/20229:22AMDow Jones NewsNovartis, Incyte: CHMP Backs Jakavi in Graft-Vs-Host DiseaseNASDAQ:INCYIncyte Corporation
      03/25/20228:30AMBusiness WireIncyte Announces Positive CHMP Opinion for Ruxolitinib (Jakavi®) for the Treatment of Acute and Chronic Graft-Versus-Host DiseaseNASDAQ:INCYIncyte Corporation
      03/23/20224:02PMEdgar (US Regulatory)Initial Statement of Beneficial Ownership (3)NASDAQ:INCYIncyte Corporation
      03/19/20223:43AMBusiness WireIncyte gibt bekannt, dass mehrere Abstracts aus seinem Dermatologie-Portfolio zur Präsentation auf der Jahrestagung 2022 der American Academy of Dermatology (AAD) angenommen wurdenNASDAQ:INCYIncyte Corporation
      03/18/20225:25PMBusiness WireIncyte annonce que plusieurs résumés de son portefeuille de produits dermatologiques ont été acceptés pour une présentation au congrès annuel de l'American Academy of Dermatology (AAD) de 2022NASDAQ:INCYIncyte Corporation
      03/18/20229:56AMBusiness WireIncyte Announces Multiple Abstracts from its Dermatology Portfolio have been Accepted for Presentation at the 2022 American Academy of Dermatology (AAD) Annual MeetingNASDAQ:INCYIncyte Corporation
      03/14/202212:15PMTipRanksIncyte (INCY) Gets a Hold Rating from Mizuho SecuritiesNASDAQ:INCYIncyte Corporation
      03/14/20228:00AMBusiness WireIncyte Announces U.S. FDA Has Extended the Supplemental New Drug Application Review Period for Ruxolitinib Cream (Opzelura™) for the Treatment of VitiligoNASDAQ:INCYIncyte Corporation
       Showing the most relevant articles for your search:NASDAQ:INCY